|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HERC2 |
Gene summary for HERC2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HERC2 | Gene ID | 8924 |
| Gene name | HECT and RLD domain containing E3 ubiquitin protein ligase 2 | |
| Gene Alias | D15F37S1 | |
| Cytomap | 15q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A8KAQ8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8924 | HERC2 | CA_HPV_1 | Human | Cervix | CC | 7.51e-03 | -1.56e-02 | 0.0264 |
| 8924 | HERC2 | CCI_2 | Human | Cervix | CC | 2.15e-06 | 1.05e+00 | 0.5249 |
| 8924 | HERC2 | CCI_3 | Human | Cervix | CC | 4.88e-04 | 6.48e-01 | 0.516 |
| 8924 | HERC2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.60e-22 | -6.75e-01 | 0.0155 |
| 8924 | HERC2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.34e-07 | -5.43e-01 | -0.1808 |
| 8924 | HERC2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.54e-06 | -5.44e-01 | -0.1207 |
| 8924 | HERC2 | HTA11_5212_2000001011 | Human | Colorectum | AD | 3.33e-02 | -5.94e-01 | -0.2061 |
| 8924 | HERC2 | HTA11_5216_2000001011 | Human | Colorectum | SER | 4.57e-02 | -6.25e-01 | -0.1462 |
| 8924 | HERC2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 2.67e-04 | -6.39e-01 | -0.0179 |
| 8924 | HERC2 | HTA11_4255_2000001011 | Human | Colorectum | SER | 4.57e-02 | -5.76e-01 | 0.0446 |
| 8924 | HERC2 | HTA11_9408_2000001011 | Human | Colorectum | AD | 2.17e-02 | -4.50e-01 | 0.0451 |
| 8924 | HERC2 | HTA11_8622_2000001021 | Human | Colorectum | SER | 8.01e-03 | -4.49e-01 | 0.0528 |
| 8924 | HERC2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.78e-04 | -3.81e-01 | 0.0588 |
| 8924 | HERC2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 7.09e-09 | -4.53e-01 | 0.294 |
| 8924 | HERC2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.70e-21 | 1.25e+00 | 0.281 |
| 8924 | HERC2 | A001-C-207 | Human | Colorectum | FAP | 2.32e-03 | -9.84e-02 | 0.1278 |
| 8924 | HERC2 | A015-C-203 | Human | Colorectum | FAP | 5.73e-37 | -2.32e-01 | -0.1294 |
| 8924 | HERC2 | A015-C-204 | Human | Colorectum | FAP | 1.96e-08 | -8.87e-02 | -0.0228 |
| 8924 | HERC2 | A014-C-040 | Human | Colorectum | FAP | 3.10e-08 | 4.27e-03 | -0.1184 |
| 8924 | HERC2 | A002-C-201 | Human | Colorectum | FAP | 6.39e-19 | -2.45e-01 | 0.0324 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
| hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
| hsa04120 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
| hsa041201 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
| hsa041202 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
| hsa041203 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
| hsa041204 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
| hsa041205 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
| hsa041206 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
| hsa041207 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
| hsa041208 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
| hsa041209 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
| hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
| hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
| hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa0412010 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
| hsa0412011 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
| hsa0412021 | Liver | Cirrhotic | Ubiquitin mediated proteolysis | 72/2530 | 142/8465 | 1.32e-07 | 1.97e-06 | 1.21e-06 | 72 |
| hsa0412031 | Liver | Cirrhotic | Ubiquitin mediated proteolysis | 72/2530 | 142/8465 | 1.32e-07 | 1.97e-06 | 1.21e-06 | 72 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HERC2 | SNV | Missense_Mutation | novel | c.243A>C | p.Lys81Asn | p.K81N | O95714 | protein_coding | tolerated(0.06) | benign(0.066) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| HERC2 | SNV | Missense_Mutation | novel | c.1622N>C | p.Ile541Thr | p.I541T | O95714 | protein_coding | deleterious(0) | benign(0.292) | TCGA-EO-A3AU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| HERC2 | SNV | Missense_Mutation | novel | c.10097N>C | p.Lys3366Thr | p.K3366T | O95714 | protein_coding | tolerated(0.22) | probably_damaging(0.991) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
| HERC2 | SNV | Missense_Mutation | rs146210640 | c.797N>T | p.Thr266Met | p.T266M | O95714 | protein_coding | tolerated(0.05) | probably_damaging(0.99) | TCGA-EO-A3AZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HERC2 | SNV | Missense_Mutation | rs770688775 | c.11716C>T | p.Arg3906Cys | p.R3906C | O95714 | protein_coding | deleterious(0.03) | benign(0.27) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| HERC2 | SNV | Missense_Mutation | novel | c.6963G>T | p.Leu2321Phe | p.L2321F | O95714 | protein_coding | tolerated(0.32) | probably_damaging(0.979) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| HERC2 | SNV | Missense_Mutation | rs776432681 | c.5173C>T | p.Arg1725Trp | p.R1725W | O95714 | protein_coding | deleterious(0) | possibly_damaging(0.897) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| HERC2 | SNV | Missense_Mutation | rs141981089 | c.6137N>T | p.Pro2046Leu | p.P2046L | O95714 | protein_coding | deleterious(0.02) | benign(0.017) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HERC2 | SNV | Missense_Mutation | rs776359705 | c.13358C>T | p.Ser4453Leu | p.S4453L | O95714 | protein_coding | tolerated(1) | benign(0.007) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HERC2 | SNV | Missense_Mutation | novel | c.8505G>T | p.Met2835Ile | p.M2835I | O95714 | protein_coding | tolerated(0.55) | probably_damaging(0.954) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 8924 | HERC2 | DNA REPAIR, ENZYME | NERATINIB | NERATINIB | 23220880 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |